The US Food and Drug Administration will have a new leader, after the Senate confirmed Robert Califf in a tight vote, 50 to 46, which exposed political divisions over a range of healthcare issues.
Dr Califf should be able to hit the ground running, having served as FDA Commissioner already, under Barack Obama, from February 2016 until January 2017.
As well as ongoing controversy around actions to mitigate the impact of the coronavirus pandemic, the appointment has surfaced partisan rancour around hot button topics such as abortion drug rules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze